Eagle Pharmaceuticals Company Profile (NASDAQ:EGRX)

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals declared that its board has initiated a share buyback plan on Thursday, August 10th 2017, which authorizes the company to buyback $100,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 13.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) released its quarterly earnings data on Wednesday, August, 9th. The company reported $0.33 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.18. The company had revenue of $50.10 million for the quarter, compared to analysts' expectations of $52.52 million. Eagle Pharmaceuticals had a net margin of 39.32% and a return on equity of 66.30%. The company's revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.80 earnings per share. View Eagle Pharmaceuticals' Earnings History.

4 analysts have issued 1-year price objectives for Eagle Pharmaceuticals' stock. Their predictions range from $37.00 to $97.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $72.50 in the next twelve months. View Analyst Ratings for Eagle Pharmaceuticals.

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (7/31/2017)
• 2. Mizuho analysts commented, "We remain cautious on 2017 revenue, the exertional heat stroke (EHS) launch, and lower takeout probability: Eagle reported 4Q:16 revs of $81.1M and GAAP EPS of $3.52 vs. FactSet consensus $86.0M and $2.82. Mgmt introduced FY:17 SG&A guidance of $65-$68M and $31-$35M in R&D. Consensus models are in line with these expense ranges, but we think that 2017 revenue expectations (particularly Ryanodex) need to come down based on a slower EHS ramp. Because we now have a better appreciation for the hurdles associated with this launch, we also lowered our probability of takeout to 40%, from 50% previously. On a standalone basis, we think that EGRX is only worth $54/share so the stock already reflects expectations of a takeout, in our view. We reiterate our Underperform rating and $66 PT, which are based on a weighted blend of DCF ($54) and SOTP ($85) valuations." (3/17/2017)

Some companies that are related to Eagle Pharmaceuticals include Aimmune Therapeutics (AIMT), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), NOVAN INC (NOVN), CorMedix (CRMD), Check-Cap (CHEK), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).

Eagle Pharmaceuticals' management team includes the folowing people:

• Michael Graves, Independent Chairman of the Board
• Scott L. Tarriff, Chief Executive Officer, Independent Director
• Pete A. Meyers, Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• David E. Riggs, Chief Financial Officer
• Steven L. Krill Ph.D., Executive Vice President, Chief Scientific Officer
• Adrian J. Hepner M.D. Ph.D, Executive Vice President, Chief Medical Officer
• Douglas L. Braunstein, Independent Director
• Richard A. Edlin, Independent Director
• Sander A. Flaum, Independent Director
• Robert L. Glenning, Independent Director

Eagle Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Eqis Capital Management Inc. (0.04%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Michael Graves, Pete A Meyers, Proquest Investments Iv, LP, Proquest Management Llc, Richard A Edlin, Sander A Flaum, Sander A Flaum, Scott Tarriff, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Eagle Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Michael Graves, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of Eagle Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Eagle Pharmaceuticals stock can currently be purchased for approximately $49.60.